Extended follow-up data from the phase 3 study (20 months after reported topline data, median follow-up 58 months) confirmed a statistically significant and clinically meaningful improvement in prosta ...

MEDIPOST has met all primary and secondary efficacy endpoints in the Japan Phase 3 clinical trial of CARTISTEM®, ...

Investigators found no evidence that management consulting firms improved finances, operations, or quality of care at nonprofit hospitals.

Summary: A Phase 2 randomized clinical trial demonstrates that a single 25 mg dose of psilocybin, combined with psychotherapeutic support, provides rapid, statistically significant, and clinically ...

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced the publication of a post-hoc win ...

May 14 (Reuters) - AstraZeneca said on Thursday that a late-stage trial of Imfinzi, combined with a targeted therapy prior to ...

Nonprofit hospitals saw little payoff from management consultants, with no significant improvements in finances, operations or patient care found.

Discusses Extended Follow-Up Data From Phase 3 Trial of aglatimagene besadenovec in Localized Prostate Cancer May 15, ...

Phase 3 ACACIA-HCM trial results show aficamten significantly improves exercise capacity and quality of life in patients with symptomatic non-obstructive HCM.

The Phase 2 study is being conducted under an IND with the FDA and includes leading investigators from Vanderbilt University, ...

Phase 3 VIKTORIA-1 trial achieved primary endpoint with clinically meaningful improvement in progression-free survival in PIK3CA mutant cohort; ...